To address the unmet medical needs of our patients with paradigm-shifting therapeutics.
We derive our name from the latin word vincēre meaning
VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer.
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive lymphomas and advanced solid tumors ongoing PALO ALTO, Calif.